Prior authorization required

Precertification (prior authorization) is required for etelcalcetide (Parsabiv) for applicable Aetna commercial plans. Providers must submit a Statement of Medical Necessity (SMN) or use Specialty Pharmacy precertification processes; call (866) 752-7021 or fax (888) 267-3277 for precertification. Precertification/PA rules apply according to the member’s plan design and do not by themselves guarantee coverage — plan benefits and CPB provisions determine final benefit applicability.

• Precertification required for Parsabiv — contact numbers and SMN form instructions
• PA determinations depend on plan provisions and CPBs; precertification ≠ coverage guarantee

Etelcalcetide (Parsabiv) indication verification

Prior authorization must document the FDA‑approved indication for etelcalcetide: secondary hyperparathyroidism (SHPT) in adults with chronic kidney disease on hemodialysis. For Parsabiv, the PA should verify the member is on hemodialysis and has an iPTH baseline consistent with policy thresholds (and serum calcium ≥ 8.3 mg/dL where applicable). Off‑label use (for patients not on hemodialysis, primary HPT, or parathyroid carcinoma) is not recommended and may be denied.

• PA must confirm CKD on hemodialysis with SHPT (N18.6, N25.81, Z99.2 as applicable)
• Do not request coverage for off‑label populations (CKD not on HD, primary HPT, parathyroid carcinoma)

PA and documentation for injectable vitamin D analogues

For injectable vitamin D analogues (calcitriol, paricalcitol, doxercalciferol) a prior authorization may be required under applicable plans. When seeking coverage, submit clinically documented indication, prior therapy history, and baseline laboratory results (including serum calcium, phosphorus, and PTH). Providers must show benefit from therapy for continuation requests (improvement or stabilization in calcium/phosphorus and/or reduction in PTH).

• Provide baseline and serial labs (serum calcium, phosphorus, intact PTH) with initial and reauthorization requests
• Document prior response/benefit for continuation of therapy

Step therapy / brand exception for Parsabiv

Step‑therapy and brand‑selection requirements apply for Parsabiv: it is considered medically necessary only after contraindication, intolerance, or inadequate response to specified alternatives. The required prior treatment trials include phosphate binders, vitamin D analogs, and cinacalcet as detailed below.

• At least 2 phosphate binders tried (each ≥ 2 months)
• At least 2 vitamin D analogs tried (each ≥ 2 months)
• Therapeutic failure, contraindication, or intolerance to cinacalcet after at least a 6‑month trial at maximum tolerated dose

Preferred sequencing and consideration of oral cinacalcet

Preferred sequencing is implied: oral therapies (for example, oral calcitriol or cinacalcet) should be tried before switching to parenteral/injectable options when clinically appropriate. Consider an oral cinacalcet trial prior to IV etelcalcetide unless contraindicated or not tolerated; randomized trials compared etelcalcetide with oral cinacalcet and support considering oral therapy first.

• Consider trial of oral cinacalcet (J0604) before initiating etelcalcetide unless contraindicated
• Injectable therapy appropriate when oral therapy is insufficient, not tolerated, or contraindicated

Required claim‑level diagnosis and HCPCS linkage

Claims must include appropriate diagnosis and HCPCS linkage to support medical necessity. Use renal and SHPT ICD‑10 codes covered by this CPB and the correct HCPCS for the drug administered. Use of excluded or non‑covered ICD‑10 codes can trigger denial.

• Include HCPCS J0606 for etelcalcetide (0.1 mg) when applicable and J0604 (cinacalcet oral) is noted as not covered concurrently
• Include covered ICD‑10 codes such as N18.6, N25.81, Z99.2, and E83.51 where applicable
• Avoid submitting excluded ICD‑10 codes listed in the CPB to prevent denial

Concurrent therapy and claim denial risks

Concurrent therapy with oral cinacalcet (J0604) and IV etelcalcetide may lead to denial; do not bill both concurrently. Also be aware of other potential denial triggers when unsupported or excluded diagnosis codes are used on the claim.

• Concurrent use/billing of J0604 (cinacalcet oral) with J0606 (etelcalcetide) is not covered and may be denied
• Verify diagnosis codes match CPB‑covered indications to avoid denials

Clinical monitoring and outcome documentation

Monitoring and documentation of laboratory outcomes are expected. Trials and RCTs reported baseline and serial measures of intact PTH, serum calcium, phosphorus, bone markers (e.g., bone‑specific alkaline phosphatase, osteocalcin), and urinary markers (e.g., deoxypyridinoline‑to‑creatinine) to demonstrate response and safety (for example, hypercalcemia events with paricalcitol). Providers should submit relevant baseline and follow‑up lab data to support medical necessity and continuation requests.

• Report baseline and serial iPTH, serum calcium, and phosphorus
• Include bone markers and urinary markers when available (e.g., bone‑specific alkaline phosphatase, osteocalcin, UPCR, deoxypyridinoline)
• Document adverse events such as hypercalcemia, which was more frequent with paricalcitol in trials

Study enrollment and monitoring parameters

Study enrollment criteria and monitoring parameters from clinical trials inform prior authorization expectations: many trials enrolled patients with elevated baseline PTH and required pre‑treatment labs and specified dose adjustments for safety (for example, dose reductions when iPTH suppressed < 15 pg/mL or calcium exceeded thresholds). Use these clinical trial parameters as operational guidance when documenting medical necessity and safety monitoring.

• Trials required baseline PTH thresholds and serial monitoring during treatment
• Dose adjustments for paricalcitol and etelcalcetide were made for low iPTH or elevated calcium
• UPCR and proteinuria criteria were used in transplant paricalcitol trials

Etelcalcetide safety, contraindications, and diabetes‑related caution

Safety considerations and contraindications for etelcalcetide must be documented. Etelcalcetide is contraindicated in individuals with known hypersensitivity to the drug or its excipients. Label warnings include hypocalcemia, potential worsening heart failure, GI bleeding, adynamic bone, and common adverse reactions such as decreased blood calcium, muscle spasms, nausea, and paresthesia. Diabetic patients on hemodialysis require close monitoring for hypocalcemia and hypoglycemia interactions; avoid concurrent oral hypoglycemics when possible and monitor for cardiovascular events.

• Document known hypersensitivity — contraindication to etelcalcetide
• Monitor for hypocalcemia and related cardiac risks; exercise caution in diabetic patients and avoid combining with certain oral hypoglycemics/insulins
• Record and report adverse reactions and any cardiopulmonary or GI safety concerns

Provider responsibilities for documentation and medical necessity

Providers are responsible for supplying medical documentation to support medical necessity per the plan. Clinical Policy Bulletins assist in administering plan benefits but do not constitute coverage guarantees or medical advice. Ensure submitted documentation includes indication, prior therapies, baseline and serial labs, and adverse event monitoring to support authorization decisions.

• Include documentation of indication, prior treatment trials, and baseline/serial labs with PA requests
• CPB is a plan administration aid — final coverage depends on plan benefits and PA determination
• Treating providers remain responsible for clinical care and monitoring